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Purpose. The aim of the present study was to characterize the cell of the human periosteum using immunohistological and
molecular methods. Methods. Phenotypic properties and the distribution of the cells within the different layers were investigated
with immunohistochemical staining techniques and RT-PCR, focussing on markers for stromal stem cells, osteoblasts, osteoclasts
and immune cells. Results. Immunohistochemical results revealed that all stained cells were located in the cambium layer and that
most cells were positive for vimentin. The majority of cells consisted of stromal stem cells and osteoblastic precursor cells. The
density increased towards the deeper layers of the cambium. In addition, cells positive for markers of the osteoblast, chondrocyte,
and osteoclast lineages were found. Interestingly, there were MHC class II-expressing immune cells suggesting the presence of
dendritic cells. Using lineage-specific primer pairs RT-PCR confirmed the immunofluorescence microscopy results, supporting
that human periosteum serves as a reservoir of stromal stem cells, as well as cells of the osteoblastic, and the chondroblastic lineage,
osteoclasts, and dendritic cells. Conclusion. Our work elucidates the role of periosteum as a source of cells with a high regenerative
capacity. Undifferentiated stromal stem cells as well as osteoblastic precursor cells are dominating in the cambium layer. A new
outlook is given towards an immune response coming from the periosteum as MHC II positive immune cells were detected.
1. Introduction
Periosteum is a bilayered membrane associated with bone.
It is located at the boundary between the surrounding soft
tissues and the cortical bone to which it is anchored through
Sharpey’s fibers. It forms a fibrovascular membrane covering
the external surface of the bone, except for any articular
cartilage, ligament, or tendon insertions. The periosteal
membrane consists of an outer fibrous layer containing the
blood vessels and nerves, which supply the bone, and an
inner osteogenic (cambium) layer, which lies adjacent to
the bone. The cells of the cambium layer are embedded in
a loose connective tissue and are surrounded by a dense
microcirculation. Cells of the cambium layer have been
shown to contribute to fracture healing in animal models [1].
Generally, periosteal cells are important for fracture healing
and bone remodeling [2], and in children, the cambium layer
contributes to external appositional bone growth. In both
children and adults, the periosteum provides a pool of pro-
genitor cells endowed with the potential to differentiate into
an osteochondrogenic cell lineage as part of the fracture heal-
ing process [3, 4]. However, in elderly people, the periosteum
diminishes in thickness and osteogenic potential. Periosteal
cells show high mitogenic activity immediately adjacent to
the site of injury prior to the initiation of osteochondral
differentiation [5]. Cambium cells may be activated after
mechanical stimulation, such as soft tissue trauma [6], by
infection or by some tumors [4]. Under these circumstances,
this layer is capable of inducing callus tissue formation
and osteogenesis. Ito et al. [7] suggest that the cambium
layer serves as a reservoir of undifferentiated cells that are
able to differentiate into lineages of both osteoblasts and
chondrocytes. The ability of cambium cells to differentiate
2 The Scientific World Journal
into chondrocytes has stimulated more recent interest in
using periosteal grafts for the resurfacing of full thickness
articular cartilage defects. Therefore, periosteal autografts
have been used as flaps with the cambium cell layer facing
towards the defect the articular cartilage [8]. In addition,
periosteum has also been described as being able to induce
heterotopic bone formation when implanted into muscle as a
free graft.
There is a wide range for the use of periosteum in clinics.
It can be used in stimulating growth in the shorter limb
in patients, for example, with lower limb discrepancy via
periosteal stripping [9] or as a promising cellular candidate
for bone tissue engineering [10]. Considerable attention
has been focused on its rich osteogenic properties and its
potential as a tissue engineering material for use in the repair
of bone defects.
Despite the paramount importance of knowing the prop-
erties and distribution of periosteal progenitor cells, little has
been published on the characterization and quantification
of human periosteal stem cells. Consequently, the present
study aimed to characterize human periosteal cells using
immunohistologicaland molecular methods by investigating
phenotypic properties and the distribution of osteogenic
stem cells in the different layers of periosteum. Of particular
interest was the identification of osteoblast, chondrocyte, and
osteoclast lineages.
2. Methods
2.1. Periosteum Samples. A total of 15 periosteal explants
(10 × 5mm2) were taken from the medial aspect of proximal
tibia of patients who underwent orthopedic surgical proce-
dures at the proximal tibia. Seven samples were stained by
immunohistochemistry, and other eight samples were pro-
cessed for reverse transcription polymerase chain reaction
(rt-PCR). The age of the tissue donors varied between 18 and
62. The study group included eight males and seven females.
Research approval and ethics clearance were acquired from
the Royal PerthHospital HumanResearch Ethics Committee,
and, written informed consent was obtained from all study
participants.
Selection criteria for periosteal tissue donation included
intact periosteum; absence of any severe medical condition;
and being aged between 18 and 65 years. Postharvest exclu-
sion criteria included tissue damage during harvesting, with
loss of one of the layers; absence of a clear distinction between
the fibrous and cambium layer; artifacts (folding, tearing,
dehydration, cleavage, and overstaining); and improper ori-
entation during sectioning.
2.2. FluorescenceMicroscopy. The fresh periosteumwas care-
fully removed from the underlying bone using blunt for-
ceps in order to keep the fibrous and the cambium layers
intact. In some cases, a portion of underlying bone and
overlying muscle tissue was also extracted. The periosteal
tissue was immediately fixed in 1% paraformaldehyde in
0.1M sodium phosphate buffer (pH 7.2) for at least 4 hours.
The samples were subsequently frozen in liquid nitrogen
and mounted vertically into OCT compound (Tissue-Tek
no. 4583, Thuringowa, QLD, Australia) for cryosectioning
and in order to make sure that the entire thickness of the
periosteum was included in the sections. Cryosectioning was
done with a Leica Cryostat CM 30505 (Leica Microsystems
Nussloch GmbH, Nussloch, Germany). 8 𝜇m thick cross-
sections were cut at a temperature of −15∘C.The first sections
were stained with hematoxylin/eosin to check the orientation
of the periosteum and to ensure that both the cambium and
the fibrous layer were completely included (for representative
example see Figure 1).
For immune staining, the samples were incubated with
0.2% Triton X-100 in phosphate buffer saline (PBS) for
10 minutes at room temperature. For (tartrate-resistant
acidic phosphatase stain TRAP, the cells were processed
according to a fluorescence-based protocol [11, 12]. Briefly,
the cells were incubated for 15min with ELF97 substrate
(20𝜇M, E6569; Molecular Probes) in 110mM acetate buffer
(pH 5.2) containing 1.1mM sodium nitrite and 7.4mM tar-
trate (Sigma Aldrich). The nuclei were stained with DAPI
(4󸀠,6-diamidine-2󸀠-phenylindole dihydrochloride, 10 ng/mL;
Roche Diagnostics, Mannheim, Germany).
Antibodies against the following epitopes were used
for immune staining: Stro-1 (mAB mouse IgGI, hybridoma
supernatant, Developmental Studies Hybridoma Bank
at the University of Iowa), alkaline phosphatase (ALP:
hybridoma cell supernatant clone B4-78, Developmental
Studies Hybridoma Bank at the University of Iowa), vimentin
(mAB mouse VIM-13.2 clone, mouse ascites fluid, Sigma),
MHC class II (Dako, Glostrup, Denmark), CD3 (CB3G
clone, Hybridoma supernatant, 1 : 100 dilution, Eppler et
al. 1996), and core binding factor alpha-1 (Cbfa-1)/runt-
related transcription factor 2 (Runx2) (1 : 100 dilution,
rabbit polyclonal antibody, Alpha Diagnostic Intl. Inc.).
The following secondary antibodies were used: Donkey
anti-mouse AlexaFluor 488, Donkey anti-mouse AlexaFluor
555, Donkey anti-rabbit AlexaFluor 488 and Streptavidin
AlexaFluor 546 (all from Invitrogen/Molecular Probes).
All steps were performed at room temperature. Finally, the
stained sections were mounted in fluorescent mounting
medium (Dako). Fluorescent samples were analyzed and
documented using confocal microscopy (Bio-Rad MRC
1024, Coherent Enterprise argon ion 250-mW multiline
UV, American laser 100-mW argon ion multiline laser, and
Melles Griot 0.5-mW green helium-neon laser; Bio-Rad,
Hercules, CA, USA). Conventionally stained samples were
documented and analyzed with Nikon Eclipse 90 I (Nikon
Corporation, Kawasaki, Japan) and Nikon Digital Eclipse
DXM using ACT-1 software 1200 (Nikon Corporation,
Kawasaki, Japan). For all stainings, negative controls were
included without the first antibody. No unspecific staining
was detected for the antibodies and concentrations used in
this study.
2.3. Real-Time Reverse Transcription Polymerase-Chain Reac-
tion. After excision and making sure that no bone or muscle
tissue was included, the periosteal tissue was immediately
dissected into 1 mm pieces with a surgical knife. This was
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Figure 1: (a) Conventional light microscopy. Hematoxylin and eosin-stained periosteum samples showing the cell rich cambium layer and
the upper fibrous layer. (b) Fluorescence microscopy demonstrating a DAPI stain showing the distribution of nuclei (blue).
Table 1: Specific primers used for RT-PCR.
Gene Annealing temperature Application of primer Forward and reverse primers (5󸀠 → 3󸀠)
ALP 50.0
∘C Forward ACG TGG CTA AGA ATG TCA
51.0∘C Reverse CTG GTA GGC GAT GTC CTT A
Cbfa-1/Runx2 48.0
∘C Forward TCT TCA CAA ATC CTC CCC
48.0∘C Reverse TGG ATT AAA AGG ACT TGG
RANK-L 58.0
∘C Forward CCT ACG CAC AAG GCG AAG ATG C
58.0∘C Reverse CGT AGA CCA CGA TGA TGT CGC C
M-CSF 50.0
∘C Forward CTG ACC AGC TCA GAG AGA
44.0∘C Reverse CTC ATC AAT GTG CAG GA
SP7-s 55.0
∘C Forward CAG GTT CCC CCA GGA GGA
58.0∘C Reverse AGT CCC GCA GAG GGC TAG AG
SP7-l 56.0
∘C Forward TCC TCC CTG CTT GAG GAG GA
58.0∘C Reverse AGT CCC GCA GAG GGC TAG AG
Sox-9 57.0
∘C Forward GCC ACG GAG CAG ACG CAC
55.0∘C Reverse GCG CCT GCT GCT TGG ACA
TRAP 60.0
∘C Forward CTG GCT GAT GGT GCC ACC CCT G
60.0∘C Reverse CTC TCA GGC TGC AGG CTG AGG
CTR 53.0
∘C Forward GCA ATG CTT TCA CTC CTG AGA AA
53.0∘C Reverse AGT GCA TCA CGT AAT CAT ATA TC
Cathepsin K 50.0
∘C Forward CCC GAA GGG AAA CAA GCA




immediately followed by extraction of total RNA using the
Ultraspec TM-II RNA Isolation system (Biotecx Laboratories
Inc., Houston, TX, USA) in accordance with product guide-
lines. Onemicrogramof total RNAwas reverse transcribed to
complementary DNA (cDNA) using Promega Reverse Tran-
scription System (Promega Corporation, WI, USA). Real-
time quantitative PCR was performed using the iQ SYBR
Green Supermix (Bio-Rad, Regents Park, NSW, Australia)
and the Rotor-Gene 3000 cycler and corresponding software
(Corbett Life Science, Mortlake, NSW, Australia). Using
gene-specific primers (see Table 1) for human cDNA, 1 𝜇g of
cDNA was amplified for the following genes: alkaline phos-
phatase, Cbfa-1/Runx2, RANK-L, M-CSF, SP7-s (short splice
variant of Osterix), SP7-l (long splice variant of Osterix), Sox-
9, TRAP, calcitonin receptor (CTR), cathepsin K, and 𝛽-actin
(positive control). The fluorescence profile during amplifica-
tion was controlled, and only samples in which the signal
remained at baseline level during early cycles, increased
exponentially, and finally reached a plateau phase at high-
cycle numbers, were used. In addition the quality of PCR
products were tested by including the melting/dissociation
curve and detection of corresponding molecular product
weight on agarose gels. Only results complying with this
quality control were included.
3. Results
3.1. Characterization and Quantification of Cells by Immuno-
fluorescence. Cryosectionswere first stained for conventional
light microscopy with hematoxylin and eosin (a) in order
to make sure that both periosteal layers were included on
the section (Figure 1). In comparison, just the nuclei of
the two different layers were seen on the DAPI stain (b).
Subsequently, the sections were processed with specific stains
for fluorescence microscopy.The samples were then analyzed







Figure 2: Confocal fluorescence microscopy (a–c) of representative cells located in the cambium layer and stained for markers of the
osteoblast lineage. Nuclei were stained with DAPI (blue). (a) Stromal cells stained positive for vimentin (green). (b) Stromal stem cells stained
positive for Stro-1(green). (c) Cells of the osteoblast lineage stained positive for Cbfa-1/Runx2 (green).
5𝜇m
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Figure 3: Confocal fluorescence microscopy of cells located in the cambium layer and stained for Cbfa-1/Runx2. (a) Merged fluorescence
image showing in blue the nuclear DAPI stain and in green the staining for Cbfa-1/Runx2. (b) Cbfa-1/Runx2 staining in black and white, note
the nuclear expression pattern (arrow) in addition to the distinct cytoplasmic expression pattern. (c) Nuclear stain only in black and white.
using confocal microscopy.The fibrous layer, which stabilizes
the periosteum, consisted largely of a dense, cell poor con-
nective tissue. The cells had a fibroblastic spindle-like shape
and were of uniform size. There was no specific staining of
cells in the fibrous layer for the markers used. In contrast,
the immunohistochemical evaluation of the cambium layer,
which is the interface between the periosteal fibrous layer
and the outer cortical bone, revealed a cell rich tissue with
a variety of different cell types (Figures 2–4).
3.2. Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR). Periosteal samples were tested for additional mark-
ers using real-time RT-PCR due to the lack of antibodies





Figure 4: Confocal fluorescence microscopy of a representative osteoclast-like cell positive for TRAP (a) and an immature dendritic cell
positive for intracellular MHC class II (b).
specific for certain markers and also in order to confirm
the histological results. We were interested in identifying the
presence of osteoblast-, osteoclast-, and chondrocyte-related
cell populations. Markers of osteoblasts included M-CSF,
Cbfa-1/Runx2, SP7/Osterix (long and short splice variants),
RANK-L, and ALP. Sox-9 was used as a chondrocyte marker.
TRAP, cathepsin K, and CTRwere used as osteoclast markers
(Table 1).
M-CSF and CBFA-1/Runx2 were highly expressed. Rank-
L was expressed almost as highly. Expression of SP7-s and
ALP was detected at lower amounts than the other osteoblas-
tic markers. There was no detection of SP7-l. The finding
of mRNA expression of Cbfa-1/Runx2, Osterix, ALP, M-CSF
and RANK-L indicated that there were cells of the osteoblast
lineage in the periosteum. Interestingly, the mRNA for the
transcription factor Sox-9 was also detected. This is a marker
for chondroprogenitor cells and a nuclear transcription factor
that plays an essential role in chondrogenesis. All osteoclastic
markers including calcitonin receptor, TRAP, and cathepsin
K were expressed, confirming the presence of osteoclasts or
their late precursors in the periosteum.
In summary, we can say that RT-PCR results (sum-
marized in Table 2) confirmed the immunofluorescence
findings. Stromal stem cells as well as osteoblastic cells
were stained positively using specific markers (Stro-1, Cbfa-
1/Runx2, vimentin). The expression of osteoblastic markers
(CBFA-1/Runx2, ALP, SP7/Osterix, M-CSF, and RANK-L)
supports the immunohistochemical findings. Immunofluo-
rescence microscopy also revealed the existence of TRAP
and MHC class II positive cells, suggesting the presence of
osteoclasts and dendritic cells, respectively. Positive findings
of transcripts of osteoclastic markers (CTR, TRAP, and
cathepsinK) aswell as of osteoclast differentiation factors that
are expressed by osteoblasts (M-CSF, RANK-L) emphasize
the presence of osteoclasts.
4. Discussion
Open fractures but also bone tumors are just one of the
samples bone defects can arise from. Current knowledge












suggests that the periosteum, a fibrous tissuewhich covers the
surface of all bones, contains a population of progenitor cells
which mediate the repair of bone defects. Exogenous growth
factors or allografts are often used to bridge bone defects.
Over the last years many efforts have been made in order
to identify natural sources of osteogenic cells for the success
of bone bioengineering. Among them, periosteum tissue has
emerged as an interesting candidate. Its cambium layer offers
a biological reservoir of stromal stem. The multipotency and
growth characteristic of periosteum-derived progenitor cells
is known [13]. Therefore, isolated single periosteal cells or
freshly harvested periosteum are known to have chondro-
genic and osteogenic potential and are popular materials for
tissue engineering.Harvested periosteum tissue itself can also
be used as a natural scaffold in a variety of clinical applications
such as repair of cartilage defects [14] or enhancement of
soft tissue fixation to bone [15]. Therefore, flaps of periosteal
autografts have been frequently used for the repair of articular
cartilage [16]. In the management of recalcitrant nonunions
with small gaps, both periosteal and corticoperiosteal flaps
play a central role [17]. To bridge segmental bone defects Li
et al. implantedCbfa-1 gene-modified tissue-engineered bone
and vascularized periosteum.Herein, defects were stimulated
by osteogenesis, osteoinduction, and osteoconduction [18].
6 The Scientific World Journal
Even in the treatment of postradiation-induced fractures
or chronic nonunions with poor chances of spontaneous
healing and a concomitant small skin defect, the transfer
of free combined vascularized corticoperiosteal-cutaneous
flaps seems to be ideally suited [19]. Free bone or periosteal
flaps from the medial femoral condyle are being employed
for treatment of recalcitrant nonunions. When harvested in
a corticocancellous fashion, these flaps have the potential
to compromise the stability of the femur [20]. Periosteal
grafts provide successful reconstruction of skeletal problems
of the distal radius, wrist, and hand [21]. Previous studies
showed that periosteum and endosteum are major local
sources for skeletal progenitors with distinct osteogenic
and chondrogenic potentials [22]. The osteogenic potential
of periosteum has been investigated in several models. In
an experimental rabbit study, heterotopic ossification was
explored. Herein, periosteum was elevated as a vascular-
ized flap and showed strong osteogenic capacity [23]. As
Castro-Silva et al. describe periosteal-derived cells present
an interesting potential to differentiate in mature osteoblasts
able to promote mineralization in vitro by incorporating to
ECM circulating calcium from extracellular compartment
[24]. Stro-1 positive cells as detected in our samples may
undergo proliferation and differentiation into chondroblasts
and osteoblasts [25]. More than half of the detected cells
were positive for stro-1 demonstrating the presence of stromal
stem cells particularly in the deep layer of the cambium
indicating that the periosteum contains its own residential
stem cell population. Besides, we noticed, coming closer to
the cortical bone, that the number of stro-1 positive cells
increased the proposing of the cell layer responsible for the
regenerative capacity of the periosteum which lies directly
on the cortical side of the bone (deeper cambium layer).
Consequently, the fact of having Stro-1 positive stromal stem
cells in the cambium layer offers an explanation as to why
periosteum maintains the potential of inducing its cells to
differentiate into a variety of lineages including osteoblasts
and chondrocytes [1, 4, 7, 26].
As interesting as the fact that these cells might stim-
ulate bone growth, they also potently modulate immune
responses, exhibit healing capacities, improve angiogenesis,
and prevent fibrosis [26]. Most interestingly, in regard to
immune response modulation, we also found scatteredMHC
II expressing cells in the cambium layer of the periosteum
which was not described before. These MHC II positive cells
are most likely immature dendritic cells, collecting antigens
in this tissue before migrating towards the regional lymph
nodes [27]. As none of the patients had an infection or
a tumor, cells positive for MHC II were infrequent which
presumes that periosteum is one organ in the chain of the
immune response. During an inflammatory process, cells
might be multiplied which explains why the average of MHC
II positive cells differed among the tissue samples.
Matrix resorbing cells play an important role in the
removal of bone debris after injury and in extracellularmatrix
remodeling [28]. According to Fan et al. the number of
osteoclasts is higher coming along with a thicker cambium
layer in osteoporotic rats [29]. In our study the presence of
osteoclasts or their precursors was detected with molecu-
lar and morphological methods. Expression of mRNA for
additional osteoclast markers CTR and cathepsin K was also
found. TRAP positive cells were mainly found in the deeper
layer of the cambium layer close to the outer cortical bone
which affirms the findings of Fan et al..
Taken together, it is interesting that there are both
dendritic cells and osteoclasts located in the same tissue, as
both cell types derive from the samemyeloid precursors [30–
32]. Either both cell types have already committed themselves
towards one or the other sublineage before entering the tissue
or there are separate niches for the differentiation of the two
functionally different cell types, especially as there were no
TRAP and MHC II double positive cells detected in our
samples. RANK-L is an activating factor for dendritic cells
[33] as well as for osteoclasts. In contrast,Miyamoto et al. [32]
suggest that addition ofM-CSF inhibits thismaturational step
for dendritic cells potently modulating immune responses.
M-CSF and RANK-L, expressed on osteoblasts, provide the
differentiation and survival signal of these cells [3, 27, 34].
Both M-CSF and RANK-L have been shown to be expressed
in the periosteum in this study, indicating that there are func-
tional osteoblast-like cells recruiting and interacting with
osteoclast precursors. Finally, both cell types were detected in
lower numbers than stromal stem cells or osteoblastic precur-
sor cells indicating a higher capacity towards regeneration.
Besides, these cells might be a novel target to be addressed in
the treatment of osteoarthritis, rheumatoid arthritis, genetic
bone, and cartilage disorders as well as bone metastasis. But
also bone healing commenceswith an inflammatory reaction,
which initiates the regenerative healing process leading in
the end to reconstitution of bone. An unbalanced immune
reaction during this early bone healing phase is hypothesized
to disturb the healing cascade in a way that delays bone
healing and jeopardizes the successful healing outcome.
Furthermore, microscopic detection of Cbfa-1/Runx2+
cells in the cambium layer and detection ofmRNA expression
for osteoblastic markers (Cbfa-1/Runx2, M-CSF, RANK-
L, Osterix, and ALP) indicate that there are cells already
committed to the osteoblast lineage.Differences in expression
levels for the different osteoblastic markers may indicate a
variety of cells at different stages of differentiation. Especially,
Cbfa-1/Runx2 is a prerequisite of osteoblast differentiation.
Enzyme activity of ALP is believed to be one of the major
characteristics of osteoblasts [35]. This may be similar to
Stro-1 positive human marrow stromal cells. Ahdjoudj et
al. [36] found clonal expressed mRNA markers, or protein,
of the osteoblast lineage, the chondrocyte lineage, and even
the adipocyte lineage, suggesting a common precursor stage
for the three lineages. Depending on close surrounding
environment and the influence of specific transcription fac-
tors, the precursor cells may differentiate into osteoblasts,
chondrocytes, or adipocytes [37, 38]. In addition, it explains
why periosteum is so important for bone fracture healing and
callus formation, as Stro-1 positive cells may undergo prolif-
eration and differentiation into chondroblasts and osteoblasts
[25].
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Osterix plays a crucial role in segregating the osteoblast
and chondrocyte lineages from bipotential osteochondropro-
genitor cells during bone formation. Having detected expres-
sion of Osterix in this study indicates that there are cells
committed to the osteoblastic lineage in the cambium layer.
Osterix fulfills its function by inhibiting Sox-9 expression
and by fully establishing the osteoblast phenotype [39].
Nonetheless, the nuclear transcription factor Sox-9, which
has been reported to be expressed in all chondroprogenitors
and which has an essential role in chondrogenesis [40], was
found to be expressed in human periosteum in our study.This
underlines that there are progenitor cells with the potential
of becoming chondrocytes in the cambium layer. In contrast
to our findings, Ball et al. did not find a positive marker for
mature chondrocytes [41].
The present study characterized and quantified human
periosteal cells with immunohistochemical and molecular
methods. Cells of the osteoblastic and the chondroblastic
lineage, as well as their precursor stages, were detected in
the cambium layer of the human periosteum. In addition,
osteoclasts and dendritic cells were also localized in the same
layer. Hopefully, this study provides further incentive for
future investigation of the function and interplay of human
periosteal cells. In sum, ourwork elucidates the role of perios-
teum as a source of cells with a high regenerative capacity.
Undifferentiated stromal stem cells as well as osteoblastic
precursor cells are dominating in the cambium layer. A
new outlook is given towards an immune response coming
from the periosteum as MHC II positive immune cells were
detected. Instead of using exogenous growth factors and in
order to advance therapeutic protocols to solve posttraumatic
or degenerative bone lesions, periosteum should be explored
more intense as an available biological answer.
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